Patents Assigned to Xencor, Inc.
  • IgG Immunoglobulin Variants with Optimized Effector Function
    Publication number: 20100317834
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Application
    Filed: August 24, 2010
    Publication date: December 16, 2010
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
  • Optimized Proteins that Target Ep-CAM
    Publication number: 20100311954
    Abstract: Humanized Ep-CAM-targeting antibodies and methods of making and using the same are provided.
    Type: Application
    Filed: March 15, 2010
    Publication date: December 9, 2010
    Applicant: Xencor, Inc.
    Inventors: Aaron K. Chamberlain, John R. Desjarlais, Gregory Alan Lazar
  • Methods of Generating Variant Proteins with Increased Host String Content
    Publication number: 20100190247
    Abstract: The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods.
    Type: Application
    Filed: March 12, 2010
    Publication date: July 29, 2010
    Applicant: Xencor, Inc.
    Inventors: Gregory ALAN Lazar, John R. Desjarlais, Philip W. Hammond
  • Method of treatment using adiponectin variants
    Patent number: 7749956
    Abstract: A method of treating a mammal with an adiponectin mediated disorder comprising administering a therapeutically effective amount of an adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: July 6, 2010
    Assignee: Xencor, Inc.
    Inventors: Jonathan Zalevsky, Duc-Hanh Thi Nguyen, Gregory L. Moore, Sergei A. Ezhevsky, John R. Desjarlais, Arthur J. Chirino, Darian Cash, Matthew J. Bernett
  • Adiponectin variants
    Patent number: 7709607
    Abstract: An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: May 4, 2010
    Assignee: Xencor, Inc.
    Inventors: Jonathan Zalevsky, Duc-Hanh Thi Nguyen, Gregory L. Moore, Sergei A. Ezhevsky, John R. Desjarlais, Arthur J. Chirino, Darian Cash, Matthew J. Bernett
  • Optimized Antibodies that Target HM1.24
    Publication number: 20100104557
    Abstract: The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one one modification relative to a parent antibody that alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.
    Type: Application
    Filed: September 18, 2007
    Publication date: April 29, 2010
    Applicant: Xencor, Inc.
    Inventors: Matthew J. Bernett, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Umesh S. Muchhal, Duc-Hanh Thi Nguyen, John O. Richards
  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20100080814
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: September 17, 2009
    Publication date: April 1, 2010
    Applicant: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton
  • Treatment of TNF-? related disorders with TNF-? variant proteins
    Patent number: 7687461
    Abstract: The invention relates to novel proteins with TNF-alpha antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-alpha related disorders.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: March 30, 2010
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Anton Filikov, Paul Michael Steed, Jonathan Zalevsky, David Edmund Szymkowski
  • Pharmaceutical compositions of adiponectin variants and methods of storage
    Patent number: 7678886
    Abstract: A composition comprising an adiponectin variant at a concentration of at least 2.0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4° C. for one week in 10 mM PO4, 150 mM NaCl buffer.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: March 16, 2010
    Assignee: Xencor, Inc.
    Inventors: Jonathan Zalevsky, Duc-Hanh Thi Nguyen, Gregory L. Moore, Sergei A. Ezhevsky, John R. Desjarlais, Arthur J. Chirino, Darian Cash, Matthew J. Bernett
  • Optimized Fc variants and methods for their generation
    Patent number: 7662925
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: February 16, 2010
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen Kohl Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Pharmaceutical compositions for the treatment of TNF-? related disorders
    Patent number: 7662367
    Abstract: The invention relates to a pharmaceutical composition comprising a variant TNF-? protein that inhibits the activity of soluble TNF-? while substantially maintaining the activity of transmembrane TNF-? a buffer and a tonicity agent wherein said composition has a pH from approximately 5.0 to 8.0.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: February 16, 2010
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Paul Michael Steed, Jonathan Zalevsky, David Edmund Szymkowski, David F. Carmichael
  • Methods of generating variant antibodies with increased host string content
    Patent number: 7657380
    Abstract: The present invention relates to novel methods for generating variant proteins with increased host string content by comparing a parent protein sequence with two or more natural protein sequences from a host species, analyzing one or more amino acid strings of the parent protein sequence with a structurally corresponding amino acid string of each of said natural protein sequences, substituting one or more amino acid strings of the parent protein sequence with a structurally corresponding amino acid string of one of the two or more natural protein sequences on an amino acid string by amino acid string basis so that the variant protein has increased host string content, and, synthesizing and screening the variant protein.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: February 2, 2010
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond
  • HUMAN EQUIVALENT MONOCLONAL ANTIBODIES ENGINEERED FROM NONHUMAN VARIABLE REGIONS
    Publication number: 20100004431
    Abstract: The present invention is directed to the creation of human equivalent CDRs and antibodies containing them by a method of producing an antibody which specifically binds to an antigen.
    Type: Application
    Filed: April 20, 2009
    Publication date: January 7, 2010
    Applicant: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John R. Desjarlais
  • PEGylated TNF-? variant proteins
    Patent number: 7642340
    Abstract: The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.
    Type: Grant
    Filed: August 8, 2005
    Date of Patent: January 5, 2010
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Jonathan Zalevsky
  • Methods for rational pegylation of proteins
    Patent number: 7610156
    Abstract: The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: October 27, 2009
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Jonathan Zalevsky, Gregory L. Moore
  • Globular adiponectin variants
    Patent number: 7592423
    Abstract: An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the adiponectin variant is not glycosylated, the adiponectin variant does not have residues 1-100 relative to human adiponectin, and wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: September 22, 2009
    Assignee: Xencor, Inc.
    Inventors: Jonathan Zalevsky, Duc-Hanh Thi Nguyen, Gregory L. Moore, Sergei A. Ezhevsky, John R. Desjarlais, Arthur J. Chirino, Darian Cash, Matthew J. Bernett
  • Methods for rational pegylation of proteins
    Patent number: 7587286
    Abstract: The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: September 8, 2009
    Assignee: Xencor, Inc.
    Inventors: John Rudolph Desjarlais, Jonathan Zalevsky
  • Optimized Fc Variants and Methods for Their Generation
    Publication number: 20090214526
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: October 29, 2007
    Publication date: August 27, 2009
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen Kohl Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Optimized Fc Variants and methods for their generation
    Publication number: 20090215991
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: August 20, 2007
    Publication date: August 27, 2009
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
  • Optimized proteins that target Ep-CAM
    Patent number: 7557190
    Abstract: Humanized Ep-CAM-targeting antibodies and methods of making and using the same are provided.
    Type: Grant
    Filed: July 10, 2006
    Date of Patent: July 7, 2009
    Assignee: Xencor, Inc.
    Inventors: Maria D. Barbosa, Aaron K. Chamberlain, John R. Desjarlais